Roundup Lawsuit Settlement Calculator (2025)

The Roundup Cancer Case: A Timeline

The legal saga against Bayer (which acquired Monsanto in 2018) is one of the largest mass torts in US history. It began with a scientific classification and accelerated through a series of landmark verdicts that proved to juries that Roundup causes cancer.

Who Qualifies for a Roundup Settlement?

Not everyone who used Roundup and has cancer qualifies for a settlement. Mass tort attorneys evaluate three core elements when screening Roundup claims: a qualifying cancer diagnosis, documented Roundup exposure, and a supportable causation argument linking the two.

1. Qualifying Cancer Diagnosis

The overwhelmingly primary qualifying diagnosis is Non-Hodgkin Lymphoma (NHL) and its subtypes. This is the cancer with the strongest scientific and legal evidence linking it to glyphosate exposure. Additional related diagnoses that have been accepted in some claims include B-cell lymphoma not otherwise specified, T-cell lymphoma, chronic lymphocytic leukemia (CLL), and hairy cell leukemia. The strength of your claim depends heavily on which specific histological subtype you have, as some have stronger scientific support than others.

2. Documented Roundup Exposure

You must be able to demonstrate that you used Roundup (or a glyphosate-containing product) on a regular basis. The strongest claims come from:

• Agricultural workers who sprayed Roundup on crops, orchards, or fields
• Professional landscapers and groundskeepers
• Golf course maintenance workers
• Municipal or highway right-of-way workers
• Homeowners who regularly used Roundup in their gardens or yards for 2+ years

The threshold for "significant" exposure in most accepted claims is at least 2 years of use and more than 10 days per year. Lower exposure claims are harder to win but are not impossible, particularly if the exposure was extremely high intensity on the days it occurred.

3. Temporal Relationship

Your Roundup exposure should have preceded your cancer diagnosis by a reasonable period — typically at least 1 to 2 years. Cancer has a latency period, and attorneys look for exposure histories that are consistent with the known biological timeline of NHL development.

Non-Hodgkin Lymphoma Types Linked to Roundup

Non-Hodgkin Lymphoma is not a single disease — it is a family of over 60 different cancers that originate in the lymphatic system. The IARC's 2015 review specifically found evidence linking glyphosate to NHL. Within the broader NHL category, some subtypes have stronger litigation histories than others.

Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL is the most common NHL subtype and one of the most frequently seen in Roundup litigation. It is an aggressive, fast-growing cancer that requires immediate chemotherapy (typically R-CHOP). DLBCL plaintiffs generally have strong claims due to the disease's severity, the clarity of the diagnosis, and the substantial medical bills and lost wages it generates.

Follicular Lymphoma

Follicular lymphoma is a slow-growing (indolent) B-cell NHL. Edwin Hardeman, the plaintiff in the landmark 2019 federal trial verdict, had B-cell follicular lymphoma. Despite being slower growing, follicular lymphoma can transform into DLBCL and requires ongoing treatment, supporting substantial claims.

Mantle Cell Lymphoma

Mantle cell lymphoma is a relatively rare but aggressive NHL subtype with a poorer prognosis than many other forms. Its aggressiveness and the intensive treatment required — including stem cell transplant in many cases — mean it typically supports higher settlement values.

Burkitt Lymphoma

Burkitt lymphoma is one of the fastest-growing cancers known. It requires intensive, aggressive chemotherapy and can be life-threatening if not treated immediately. Burkitt claims are supported by the severity of the disease and the intensive medical intervention required.

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

CLL and its tissue counterpart SLL have been included in some Roundup settlement programs. The scientific evidence linking glyphosate specifically to CLL/SLL is somewhat weaker than for aggressive NHL subtypes, so these claims are typically placed in lower tiers, but they remain valid in many jurisdictions.

How Roundup Settlement Values Are Calculated

Unlike a standard personal injury case where you negotiate directly with an insurer, Roundup lawsuits operated within a structured Claims Administration Program. Bayer's MDL settlement program used a scoring system with multiple factors that determined each claimant's allocation from the settlement fund.

Cancer Type and Histological Subtype (Highest Weight)

The specific type of Non-Hodgkin Lymphoma you have is the single most important factor in your settlement value. Aggressive subtypes like DLBCL and Mantle Cell Lymphoma receive higher base values than slower-growing indolent lymphomas. Subtypes with the strongest scientific literature linking them to glyphosate receive premium values.

Cancer Stage and Severity

Stage IV disease — meaning the cancer has spread to multiple lymph node regions, the bone marrow, or distant organs — receives significantly higher compensation than earlier-stage disease. Ongoing active treatment at the time of settlement also increases claim value relative to cases in stable remission.

Exposure Intensity and Duration

The claims program applied exposure multipliers based on the number of years of Roundup use and the approximate number of days per year of exposure. Occupational users (farmers, landscapers, groundskeepers) received the highest exposure scores. The general threshold for meaningful exposure was 2+ years and 10+ days per year of use, though some programs accepted lower thresholds.

Economic Damages

Your actual medical bills, lost wages, and future medical costs serve as an economic floor beneath the settlement offer. Claimants with substantial documented medical expenses and lost income typically receive higher offers, particularly in cases where economic damages exceed the program's base allocation for their tier.

Age at Diagnosis and Life Impact

Younger claimants diagnosed with cancer face a lifetime of medical surveillance, potential relapse treatment, and long-term effects on their careers and quality of life. This life impact factor can increase settlement values for younger plaintiffs relative to older claimants with the same diagnosis and exposure profile.

Causation Strength

Cases with cleaner causation stories receive higher values. If a claimant has few or no alternative risk factors for lymphoma (no HIV, no prior immunosuppressive therapy, no family history), the causation link to Roundup is cleaner and the claim scores higher. Competing explanations that defense experts could argue reduce claim value.

Roundup vs. Other Mass Torts: How Do Settlements Compare

Understanding where Roundup settlements fall relative to other major mass torts helps contextualize what these numbers mean in the broader legal landscape.

Mass Tort	Defendant	Total Settlement	Avg per Plaintiff	Primary Harm
Roundup (Glyphosate)	Bayer/Monsanto	$10.9 billion	$100K–$250K	Non-Hodgkin Lymphoma
Camp Lejeune Water	US Government	$6.1B authorized	$100K–$500K+	Multiple cancers, conditions
Mesothelioma (Asbestos)	Various companies	$30B+ in trusts	$1M–$2.4M (trial)	Mesothelioma, lung cancer
3M Earplugs	3M Company	$6.0 billion	$2,000–$300K+	Hearing loss, tinnitus
Talcum Powder (Ovarian)	Johnson & Johnson	$8.9 billion proposed	$50K–$150K	Ovarian cancer, mesothelioma

Roundup settlements sit in the middle tier of mass tort compensation — substantially higher than many product liability cases but lower than mesothelioma claims, which benefit from decades of trust fund accumulation and dramatically higher jury verdicts. The key differentiator is that mesothelioma carries a near-100% mortality rate, while many NHL subtypes linked to Roundup are survivable with treatment.

How to Document Your Roundup Exposure

The strength of your Roundup claim depends critically on your ability to document your exposure. Attorneys reviewing your case will want to see corroborating evidence of Roundup use that predated your cancer diagnosis. Here is what to gather.

Purchase and Product Records

• Receipts from hardware stores, garden centers, or agricultural suppliers for Roundup or generic glyphosate herbicides
• Online order histories from Amazon, Home Depot, Lowe's, or farm supply websites
• Credit card or bank statements showing herbicide purchases
• Photographs of Roundup containers at your property (even if no longer present)
• Empty or partially used containers you may still have

Employment and Occupational Records

• Employment records showing your job title and duties (especially if you were a groundskeeper, landscaper, farmer, or agricultural worker)
• Pay stubs, W-2s, or 1099 forms documenting employment during the exposure period
• OSHA safety training records or Material Safety Data Sheets (MSDS/SDS) for Roundup from your employer
• Coworker statements or affidavits from people who can confirm you regularly applied Roundup
• Employer records of pesticide application logs (some states require these)

Medical Records

• Complete medical records documenting your NHL or related cancer diagnosis
• Pathology reports specifying the histological subtype of your lymphoma
• Oncology treatment records (chemotherapy, radiation, immunotherapy)
• Hospital bills and insurance explanation of benefits (EOBs)
• Any documentation of your disclosure of Roundup use to your oncologist or treating physician

Corroborating Statements

• Written or signed statements from family members who witnessed your Roundup use
• Neighbor statements if you used Roundup in a visible location
• A personal log or timeline you create now detailing your best recollection of exposure history, dates, and locations

2025 Update: Are Roundup Cases Still Being Filed?

Yes — and in significant numbers. The $10.9 billion settlement resolved claims pending as of June 2020, but it did not end Roundup litigation. There are three groups of potential claimants who may still be able to file as of 2025:

New Diagnoses After the Settlement Cutoff

People who were exposed to Roundup in the past but only recently received a cancer diagnosis may still have viable claims. The settlement's future claims fund was set up specifically for this category of plaintiffs, though access to this fund has been the subject of ongoing litigation.

Claimants Who Opted Out

Some plaintiffs chose to opt out of the class settlement to pursue their claims independently, believing their individual cases were strong enough to achieve better outcomes at trial. These cases continue in state and federal courts.

New Roundup Exposure Claims

People continue to be exposed to Roundup today — Bayer still sells it without a cancer warning in the United States. New plaintiffs who develop NHL after regular Roundup exposure can still file lawsuits, subject to their state's statute of limitations from diagnosis.

Bayer has been lobbying for federal legislation that would preempt state-law failure-to-warn claims, arguing that EPA approval of glyphosate should shield the company from liability. As of 2025, no such federal preemption legislation has passed. Courts remain divided on whether federal FIFRA (Federal Insecticide, Fungicide, and Rodenticide Act) preempts state tort claims — a question that may reach the US Supreme Court.

If you believe you have a Roundup claim, consulting a mass tort attorney as soon as possible is essential. Many work on contingency (no upfront cost) and will provide a free evaluation. Given the evolving legal landscape and strict statute of limitations deadlines, delays can permanently extinguish your right to compensation.

Frequently Asked Questions

Related Legal Calculators

Estimate compensation for other mass torts, injury claims, and legal matters: